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The data collection of antibiotic use’s expenditure for nosocromail infection treat-
ment at in-patient department was performed between 1 January 2010 to 30 June
2010. The source of information came from Infectious Control division of the hos-
pital. All information were recorded further source such as in-patient data-based
was used if the information of former source was incompleted. RESULTS: The
analysis showed that patients with nosocomial infection is 314 patients (141
male,173 female). Themost age of infection is between 71-80 years (31.53%). Build-
ing that has the most infected frequency is female medicine building (infected 35
patients (11.15%)).The most common pathogen is Acinetobacter baumannii-MDR
(25.34%) while the most origin of infection is lower respiratory tract (62.80%). Du-
ration of admission in hospital until the occur of nosocomial infection is during the
first 10 days (32.80%).The value of all antibiotics used to treat patients is
12,354,176.50 bath and the cost of eachmonth as shown in Figure 1. Sulbactam and
Cefoperazone (Sulperazon®) is themost highest cost, our data is similar trend from
previous study in other setting. Figure 1 Cost of antibiotics used in each month
(data for 6months).CONCLUSIONS: From the information obtained from this study
will make the hospital concern about strategies to prevent nosocomial infection to
reduce the loss of various and enhance the quality of life for patients.
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OBJECTIVES: to obtain information on the cost of treatment (outpatient and inpa-
tient care), including laboratory, drugs,medical supplies, consultation, Xray, room.
METHODS: A crosssectional study was done to collect data in public hospital in
East Java. Samples were 89 cases IDU with HIV, 49 of them received inpatient care.
Substitution for IDUwas not included in the study. RESULTS: Increasing number of
IDU and HIVAIDS cases in Indonesia (one province with high cases is East Java) has
lead the policy makers to provide subsidy for people living with HIVAIDS. Little is
known about the cost of treatment in hospital. It is important for both payer and
hospital to understand how best the provider payment scheme to provide services
for PLHIV. The study revealed that most of them were men, at productive age, and
come from both urban and rural area. Only 25% of them has less than 3 diagnosis
(opportunistic infection), and the rest are having more than 3 diagnosis. The top
three cases were Lung disorder, GastroEnteritis and Candidiasis. Sixty-two% of
them discharged with better condition, but 35% died. Average Length of stay was 9
days, and some of them were hospitalized more than one month. Average cost for
inpatient care was USD 547 perday and outpatient care was USD 61 for one visit.
Medical exam, drugs andhotel costswere having highest proportion. This situation
was hard for the poorwhile hospital felt total costs were not sufficiently covered by
government financing scheme for the poor. CONCLUSIONS: Cost of tretament for
PLHIV is high and in the future become serious burden for both payer and provider.
Payment to provider should consider the cost of tretament.
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OBJECTIVES: This review aimed to explore the research situation in Southeast Asian
countries on the economic evaluationof vaccination.METHODS:Asystematic literature
search was conducted in March 2012 using the Medline electronic database with the
PubMed interface. The search was limited to English-language articles published during
2001–2012. Keywords of “(analy* OR evaluat*) AND (vaccin* OR immuni*) AND (‘region/
country names’)” were employed. Themethodological quality of the studywas assessed
against the CHEC criteria list. RESULTS: Out of 1344 articles, 27 eligible articles were
retrieved and reviewed. It was found that the studies had been conducted in seven of
eleven countries in the region. Thailand had the greatest number of publications (10).
Twelve articles (44%) were written by local researchers, 19% by outside researchers, and
37% in collaboration of both. Among the articles, 56% mentioned the name of a local
researcheras thefirst or correspondingauthor. Thenumberof articles tended to increase
yearly. The types of vaccination included in the studieswere dengue, HPV, Hib, Hepatitis
A and B, HIV, influenza, Japanese encephalitis, PCV, rotavirus and varicella. Most of the
publications dealt with HPV (6) and rotavirus (6). Three studies evaluated a vaccination
program that was included in the NIP of the particular country (hepatitis B in Thailand,
and influenza and PCV in Singapore). All of the studies employed modeling. The most
frequent category of evaluation was CUA (56%), followed by CEA (15%) and CBA (11%).
Most of the studiesmet a brief CHEC criteria list, such as study population, time horizon,
perspective, discounting, and sensitivity analysis. CONCLUSIONS: An analysis was
conducted of publications focusing on the economic evaluation of vaccination in
Southeast Asian countries. Most studies were conducted by local researchers. It
can be assumed that such economic information is gaining importance in policy
decision making.
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OBJECTIVES: This study aims to assess the cost-effectiveness of rotavirus immu-
nization in Indonesia, taking breastfeeding patterns explicitly into account.
METHODS: An age-structured cohort model was developed for the 2011 Indonesia
birth cohort. Next, we compared two strategies, the current situation without ro-
tavirus immunization versus the alternative of a national program. The model
applies a 5 years time horizon, with 1month analytical cycles for children less than
1 year of age and annual cycles beyond 1 year. Four scenarios were compared:
population under 1 year oldwith 100%exclusive breastfeeding, 100%partial breast-
feeding, 100% no breastfeeding and the actual combination over the different
breastfeeding modes as present in Indonesia currently. Monte Carlo simulations
were used to examine the economic acceptability and affordability of the rotavirus
vaccination. RESULTS: Rotavirus immunization would effectively reduce severe
cases of rotavirus during the first 5 years of life. Under the GAVI-subsidized vaccine
price the vaccine cost would amount to US$ 3.7 million per annum. The incremen-
tal cost per quality-adjusted-life-year (QALY) in the base case was US$ 271 from
health care perspective; much lower than the Gross Domestic Product (GDP) per
capita of US$ 3.469 in 2011. Affordability results showed that at the GAVI-subsi-
dized vaccine price, rotavirus vaccination could be affordable for the Indonesian
health system. Vaccination is most cost-effective in case of 100% no breastfeeding.
CONCLUSIONS: Rotavirus immunization in Indonesia would be a cost-effective
health intervention with GAVI’s financial support. The results showed that rotavi-
rus immunization would greatly reduce the burden of disease due to rotavirus. It
also showed that no breastfeedingwouldmake vaccination themost cost-effective
intervention comparing to other two breastfeeding patterns.
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Streptococcus pneumonia has caused invasive diseases as meningitis and bacte-
remia and non-invasive diseases as pneumonia and acute otitis media (AOM),
leading to high morbidity and mortality in infants and the elderly in Hong Kong.
OBJECTIVES: To examine the health and economic impact of pneumococcal non-
typeable haemophilus influenza protein-D conjugate vaccine (PHiD-CV) in the pub-
lic sector of Hong Kong compared to no vaccination. METHODS: A transmission
dynamic model adapted with local data was developed to simulate multiple age-
specific cohorts progressingwith invasive pneumococcal diseases (IPD) (meningitis
and bacteremia), all-cause pneumonia, and acute otitis media (AOM) over 10 years
assuming annual universal vaccination on newborn infants with coverage rate of
90%. The study was performed from a health care payer’s perspective. Epidemio-
logical and cost data inputs were based on previously published study. Direct vac-
cine effectiveness was estimated from prior clinical trials and post-marketing
studies. 1-way and multivariate probabilistic sensitivity analyses were performed
to test the robustness ofmodel outcomes. 3%discount ratewas applied to both cost
and effectiveness. RESULTS: Model projections predicted that universal infant
PHiD-CV vaccination could prevent 74 deaths (1,553 quality-adjusted life years)
caused by IPD and hospitalized pneumonia. PHiD-CV was projected to prevent 555
additional cases of IPD, 19,706 cases of hospitalized pneumonia and 29,974 AOM
over 10-year horizon as compared with no vaccination. Assuming vaccine price of
HK$265 (including administration cost of HK$70) per dose, PHiD-CV vaccination is
estimated to save an additional HK$799.65 millions as compared with no vaccina-
tion at the total vaccination cost of HK$66.18 millions. CONCLUSIONS: PHiD-CV is
expected to have great impact in alleviating pneumococcal disease burden and to
spare considerable disease management cost in treating pneumococcal diseases.
In all, universal infant PHiD-CV vaccination is a cost-saving strategy.
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OBJECTIVES: To analyze AMR in Thailand. METHODS: A systematic review over the
period 1980 to present under the PRISMAguidelinesusing 4databases: Pubmed; Science-
direct;Healthsystemresearchinstitute (HSRI)ofThailand;andThai journalcitationindex
centre (TCI). Key words used were [health care-associated OR nosocomial OR hospital
acquired AND Economic* AND Thai*] AND [antimicrobial resistan* AND Thai*]. We also
used key words in Thai language for Thai databases. Inclusion criteria: epidemiologic
studies andpharmacoeconomic studies of bacterial resistanceofnosocomial infection in
Thailand. Exclusion criteria: pharmacokinetics, pharmacodynamics, pharmacologics,
molecularandgenomicsstudies.Studies inagriculturesandlivestockwerealsoexcluded.
RESULTS: Nineteen studies met eligible criteria in this systematic review. There
were 4 groups of study onAMR burden and situation. Theywere: 1) AMR situations:
a systems analysis; 2) AMR burden: epidemiological burden such as surveillance
studies fromNational Antimicrobial Resistance Surveillance Thailand (NARST) and
national surveillance of nosocomial infections in Thailand from 1988-2006 and
economics burden; 3) factors associated with AMR in Thailand; and 4) studies of
AMR preventions and control programs in Thailand. CONCLUSIONS: AMR is one of
themajor health problems in Thailand. The existing data lack clarity and are often unre-
liable toquantify anaccurate amount ofAMRburden.More valid and reliable data on the
use of antimicrobials and of AMR aswell asmorbidity andmortality data related to AMR
areneeded inorder to computeburdenofAMR inThailandat anational level and inform
policy decisionmaking.
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